December 04, 2025

Dana-Farber researchers to present findings at 2025 San Antonio Breast Cancer Symposium

Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.

Dana-Farber

December 01, 2025

Dana-Farber Research News 12.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 - 15.

Dana-Farber

November 21, 2025

Large AI Breast Cancer Screening Trial Increases Detection Rate by 20%

Using an artificial intelligence (AI)–integrated workflow, DeepHealth, computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more breast cancer cases than the u...

The ASCO Post

November 20, 2025

ASTRO Experts Comment on the Results of the SUPREMO Trial

While the headlines following its publication suggested that “radiotherapy can be avoided” in some patients with early-stage breast cancer, experts from the American Society for Radiation Oncology (AS...

The ASCO Post

November 12, 2025

T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer

As reported in The New England Journal of Medicine by Tolaney et al, interim analysis of the phase III DESTINY-Breast09 trial has shown significantly improved progression-free survival with trastuzuma...

The ASCO Post

September 23, 2020

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer

Alpelisib offers a groundbreaking treatment for advanced HR-positive, HER2-negative breast cancer, improving outcomes for patients with PI3K mutations (courtesy of Novartis).

JADPRO

January 20, 2020

Breast Density and Breast Cancer

A new study suggests MRI screenings could drastically reduce breast cancer intervals in women with dense breast tissue, yet guidelines for clinical practice are still unclear.

JADPRO

January 01, 0001

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Significant drug approvals in oncology are reshaping treatment pathways, highlighting progress yet pointing out the limitations of new entries as discussed by Edward Li.

JADPRO

January 01, 0001

Breast Implants and Lymphoma: What Is the Risk for Your Patient?

Breast implants can offer cosmetic enhancements and reconstruction options, but understanding the risks of BIA-ALCL is crucial for patients and clinicians alike.

JADPRO